CN100384837C - 作为抗肿瘤剂的法呢基蛋白质转移酶抑制剂 - Google Patents

作为抗肿瘤剂的法呢基蛋白质转移酶抑制剂 Download PDF

Info

Publication number
CN100384837C
CN100384837C CNB01818121XA CN01818121A CN100384837C CN 100384837 C CN100384837 C CN 100384837C CN B01818121X A CNB01818121X A CN B01818121XA CN 01818121 A CN01818121 A CN 01818121A CN 100384837 C CN100384837 C CN 100384837C
Authority
CN
China
Prior art keywords
compound
substituted
group
alkyl
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB01818121XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1471524A (zh
Inventor
F·G·恩乔罗格
B·维布尔班
A·B·库珀
T·古兹
D·F·拉尼
K·P·米诺尔
R·J·多尔
V·M·吉里亚瓦拉班
B·桑塔纳姆
P·A·平托
H·Y·朱
K·M·凯尔蒂卡
C·S·阿瓦雷斯
J·J·巴尔德温
李革
黄嘉瑜
R·A·詹姆斯
R·W·比肖普
J·王
J·A·德赛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacopeia Drug Discovery Inc
Merck Sharp and Dohme LLC
Original Assignee
Pharmacopeia Inc
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Inc, Schering Corp filed Critical Pharmacopeia Inc
Publication of CN1471524A publication Critical patent/CN1471524A/zh
Application granted granted Critical
Publication of CN100384837C publication Critical patent/CN100384837C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB01818121XA 2000-08-30 2001-08-28 作为抗肿瘤剂的法呢基蛋白质转移酶抑制剂 Expired - Fee Related CN100384837C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918300P 2000-08-30 2000-08-30
US60/229,183 2000-08-30

Publications (2)

Publication Number Publication Date
CN1471524A CN1471524A (zh) 2004-01-28
CN100384837C true CN100384837C (zh) 2008-04-30

Family

ID=22860141

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB01818121XA Expired - Fee Related CN100384837C (zh) 2000-08-30 2001-08-28 作为抗肿瘤剂的法呢基蛋白质转移酶抑制剂

Country Status (27)

Country Link
US (1) US20020198216A1 (https=)
EP (1) EP1313725B1 (https=)
JP (1) JP2004513885A (https=)
KR (1) KR20030034161A (https=)
CN (1) CN100384837C (https=)
AR (1) AR033680A1 (https=)
AT (1) ATE359281T1 (https=)
AU (2) AU2001288451C1 (https=)
BR (1) BR0113675A (https=)
CA (1) CA2420673A1 (https=)
CO (1) CO5640109A2 (https=)
DE (1) DE60127846T2 (https=)
EC (1) ECSP034494A (https=)
ES (1) ES2284686T3 (https=)
HK (1) HK1054548B (https=)
HU (1) HUP0302942A3 (https=)
IL (1) IL154528A0 (https=)
MX (1) MXPA03001849A (https=)
NO (1) NO20030918L (https=)
NZ (1) NZ524246A (https=)
PE (1) PE20020486A1 (https=)
PL (1) PL361103A1 (https=)
RU (1) RU2293734C9 (https=)
SK (1) SK2292003A3 (https=)
TW (1) TWI268280B (https=)
WO (1) WO2002018368A1 (https=)
ZA (1) ZA200301545B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
WO2003030908A2 (en) * 2001-10-09 2003-04-17 The University Of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
AU2002346644A1 (en) * 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2004094409A1 (en) 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
CA2525987A1 (en) * 2003-06-05 2005-01-06 Charles Achkar Methods of treating hyperproliferative cell disorders
CN1972712A (zh) * 2003-06-09 2007-05-30 塞缪尔·瓦克萨尔 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
ES2235611B2 (es) * 2003-07-25 2006-07-16 Universidade De Santiago De Compostela Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas.
ES2317047T3 (es) 2003-08-07 2009-04-16 Schering Corporation Nuevos inhibidores de la farnesil proteina transferasa como agentes antitumorales.
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
MX2007007611A (es) * 2004-12-21 2007-09-04 Schering Corp Nuevos inhibidores de la farnesil protein-transferasa como agentes antitumorales.
RU2361587C1 (ru) * 2008-02-14 2009-07-20 Михаил Владимирович Кутушов Лекарственное средство для лечения онкологических заболеваний
WO2010006432A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
US20220257540A1 (en) * 2019-06-28 2022-08-18 Anhui Ronghang Biotech Development Co., Ltd. Compositions and methods for treatment of hepatitis b virus infection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
WO1996030363A1 (en) * 1995-03-24 1996-10-03 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
WO2000037458A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Farnesyl protein transferase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE68935B1 (en) * 1990-06-22 1996-07-24 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene piperidylidene and piperazine compounds compositions and methods of use
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
WO1996030363A1 (en) * 1995-03-24 1996-10-03 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
WO2000037458A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Farnesyl protein transferase inhibitors

Also Published As

Publication number Publication date
ATE359281T1 (de) 2007-05-15
TWI268280B (en) 2006-12-11
EP1313725B1 (en) 2007-04-11
AU2001288451C1 (en) 2008-03-06
HK1054548A1 (en) 2003-12-05
RU2293734C2 (ru) 2007-02-20
JP2004513885A (ja) 2004-05-13
DE60127846D1 (en) 2007-05-24
AR033680A1 (es) 2004-01-07
HUP0302942A3 (en) 2007-02-28
PE20020486A1 (es) 2002-06-14
ES2284686T3 (es) 2007-11-16
NZ524246A (en) 2004-11-26
WO2002018368A1 (en) 2002-03-07
DE60127846T2 (de) 2008-03-06
AU2001288451B2 (en) 2007-05-24
SK2292003A3 (en) 2003-08-05
NO20030918D0 (no) 2003-02-27
KR20030034161A (ko) 2003-05-01
CO5640109A2 (es) 2006-05-31
MXPA03001849A (es) 2003-06-04
CN1471524A (zh) 2004-01-28
HUP0302942A2 (hu) 2003-12-29
CA2420673A1 (en) 2002-03-07
NO20030918L (no) 2003-04-29
EP1313725A1 (en) 2003-05-28
ZA200301545B (en) 2004-06-22
IL154528A0 (en) 2003-09-17
ECSP034494A (es) 2003-04-25
BR0113675A (pt) 2003-06-24
RU2293734C9 (ru) 2007-10-10
US20020198216A1 (en) 2002-12-26
AU8845101A (en) 2002-03-13
HK1054548B (en) 2007-10-18
PL361103A1 (en) 2004-09-20

Similar Documents

Publication Publication Date Title
CN100384837C (zh) 作为抗肿瘤剂的法呢基蛋白质转移酶抑制剂
AU2024204818A1 (en) Nuclear transport modulators and uses thereof
US10851098B2 (en) Azole amides and amines as alpha v integrin inhibitors
JP2002503249A (ja) 癌の治療方法
WO2014152263A1 (en) Exo olefin-containing nuclear transport modulators and uses thereof
JP7027393B2 (ja) ベンズアミド及びニコチンアミド化合物及びこれを使用する方法
TW201524952A (zh) Ｋｒａｓ ｇ１２ｃ之共價抑制劑
US7342016B2 (en) Farnesyl protein transferase inhibitors as antitumor agents
WO2003047586A1 (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
CA3121202A1 (en) Pyrrole and pyrazole compounds and methods of use thereof
AU2001288451A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
EP1674457B1 (en) Derivatives of squaric acid with anti-proliferative activity
HK40009479A (en) 1,2,4-triazoles as nuclear transport modulators and use in the treatment of specific forms of cancer
HK40009479B (en) 1,2,4-triazoles as nuclear transport modulators and use in the treatment of specific forms of cancer
HK1087122B (en) Novel farnesyl protein transferase inhibitors as antitumor agents
HK1087122A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
HK1223936B (en) 1,2,4-triazoles as nuclear transport modulators and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: PHARMECPIA DRUG R & D CO., LTD.

Free format text: FORMER OWNER: PHARMACOPEIA INC.

Effective date: 20041203

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20041203

Address after: new jersey

Applicant after: SCHERING CORP (US)

Co-applicant after: Pharmacopeia Drug Discovery

Address before: new jersey

Applicant before: SCHERING CORP (US)

Co-applicant before: Pharmacopeia Inc.

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080430

Termination date: 20090928